# Raaj Medisafe (NSE: RAAJMEDI) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/RAAJMEDI · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹97 Cr, it ranks 2697th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Packaging & Containers.

Its return on equity was 24.9% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹25 Cr (+2.8% year on year) and net profit −₹3 Cr (−192.8%), on a standalone basis. Promoters held 59.08% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹97 Cr |
| ROE | 24.9% (FY25) |
| ROCE | 18.9% (FY25) |
| Debt to equity | 1.49 |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹25 Cr | +2.8% | −₹3 Cr | −192.8% | −₹1.96 |
| Q3 FY26 | ₹21 Cr | +41.9% | ₹2 Cr | +83.5% | ₹1.44 |
| Q2 FY26 | ₹18 Cr | +47.0% | ₹2 Cr | +166.2% | ₹1.31 |
| Q1 FY26 | ₹16 Cr | +45.1% | ₹1 Cr | +50.5% | ₹1.11 |
| Q4 FY25 | ₹24 Cr | +114.8% | ₹3 Cr | +397.1% | ₹2.61 |
| Q3 FY25 | ₹15 Cr | +43.5% | ₹1 Cr | +9.6% | ₹0.76 |
| Q2 FY25 | ₹13 Cr | +11.8% | ₹1 Cr | −38.7% | ₹0.49 |
| Q1 FY25 | ₹11 Cr | +3.7% | ₹1 Cr | +54.0% | ₹0.74 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹62 Cr | ₹6 Cr |
| FY24 | ₹43 Cr | ₹3 Cr |
| FY23 | ₹39 Cr | ₹3 Cr |
| FY22 | ₹35 Cr | ₹3 Cr |
| FY21 | ₹32 Cr | ₹2 Cr |
| FY20 | ₹22 Cr | −₹0 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 59.08%
- Non-institutions: 40.92%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Mercury Labs](https://app.pivotnow.in/stock/MERCURYLAB) | — | ₹102 Cr | — | — |
| [Vaishali Pharma](https://app.pivotnow.in/stock/VAISHALI) | ₹7.49 | ₹101 Cr | 124.8 | — |
| [Concord Drugs](https://app.pivotnow.in/stock/CONCORD) | — | ₹101 Cr | — | — |
| [Denis Chem Lab](https://app.pivotnow.in/stock/DENISCHEM) | — | ₹101 Cr | — | — |
| [Fortis Malar](https://app.pivotnow.in/stock/FORTISMLR) | — | ₹97 Cr | — | — |
| [KHFM HOSPITALIT](https://app.pivotnow.in/stock/KHFM) | ₹40.90 | ₹95 Cr | — | — |

## Questions and answers

### What is the market cap of Raaj Medisafe?

Raaj Medisafe's market capitalisation is ₹97 Cr (₹97 Cr) at the 22 Oct 2026 close, ranking 2697th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Raaj Medisafe?

Return on equity was 24.9% in FY25 and return on capital employed was 18.9% in FY25 (standalone figures).

### Is Raaj Medisafe a debt-free company?

No. Raaj Medisafe's debt-to-equity ratio was 1.49 in FY25, with total debt of ₹14 Cr.

### What were Raaj Medisafe's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Raaj Medisafe reported revenue of ₹25 Cr, +2.8% year on year, and net profit of −₹3 Cr, −192.8% year on year.

### What is the shareholding pattern of Raaj Medisafe?

As of 30 Jun 2026: promoters 59.08%, non-institutions 40.92%.

### Who are Raaj Medisafe's competitors?

The listed Pharma & Healthcare companies closest to Raaj Medisafe by market cap are Mercury Labs, Vaishali Pharma, Concord Drugs, Denis Chem Lab, Fortis Malar and KHFM HOSPITALIT.

### Is Raaj Medisafe a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Raaj Medisafe's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on RAAJMEDI against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.